Literature DB >> 9175191

Representative payee practices of community mental health centers in Washington State.

R K Ries1, D G Dyck.   

Abstract

OBJECTIVE: A survey was conducted to evaluate the representative payee practices of community mental health centers (CMHCs) in Washington State, with emphasis on whether and how benefit disbursement practices were linked to patients' clinical behaviors, especially substance use.
METHODS: A survey was pilot tested with several clinicians and sent to all 80 licensed CMHCs in Washington State. Data were analyzed using t tests, Pearson r correlations, and regression analysis.
RESULTS: Of 41 responding agencies, 30 (73 percent) reported providing payee services for at least some of their patients, approximately one-third of whom had a dual diagnosis of a mental illness plus an alcohol or drug disorder. The frequency of benefit disbursement, but not the overall amount of funds disbursed, was moderately to highly linked by contingency management to patients' money management skills, substance use, and level of functioning; it was less tightly linked to treatment attendance. Larger and more experienced programs reported tighter linkage between benefit disbursement frequency and patients' behavior than did smaller programs. Responses also indicated a significant need for more clearly articulated guidelines for payee benefit management.
CONCLUSIONS: Despite a lack of studies demonstrating the effectiveness of representative payee practices, CMHCs appear to be using contingency techniques to link benefit disbursement to clinical behaviors. Further studies of these practices, their outcomes, and associated ethical issues are needed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9175191     DOI: 10.1176/ps.48.6.811

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  10 in total

Review 1.  Managing comorbid schizophrenia and substance abuse.

Authors:  R E Drake; K T Mueser
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

Review 2.  Behavioral therapies for co-occurring substance use and mood disorders.

Authors:  Kathleen M Carroll
Journal:  Biol Psychiatry       Date:  2004-11-15       Impact factor: 13.382

3.  A comparison of satisfaction with clinician, family members/friends and attorneys as payees.

Authors:  Marc I Rosen; Margaret Bailey; Elizabeth Dombrowski; Karen Ablondi; Robert A Rosenheck
Journal:  Community Ment Health J       Date:  2005-06

4.  Subjective Experiences of Clients in a Voluntary Money Management Program.

Authors:  Kristin L Serowik; Chyrell D Bellamy; Michael Rowe; Marc I Rosen
Journal:  Am J Psychiatr Rehabil       Date:  2013

5.  All-data approach to assessing financial capability in people with psychiatric disabilities.

Authors:  Christina M Lazar; Anne C Black; Thomas J McMahon; Robert A Rosenheck; Richard Ries; Donna Ames; Marc I Rosen
Journal:  Psychol Assess       Date:  2015-07-06

6.  Does the disbursement of income increase psychiatric emergencies involving drugs and alcohol?

Authors:  R Catalano; W McConnell; P Forster; B McFarland; M Shumway; D Thornton
Journal:  Health Serv Res       Date:  2000-10       Impact factor: 3.402

Review 7.  The 'check effect' reconsidered.

Authors:  Marc I Rosen
Journal:  Addiction       Date:  2011-04-28       Impact factor: 6.526

8.  Measuring money mismanagement among dually diagnosed clients.

Authors:  Ryan A Black; Bruce J Rounsaville; Robert A Rosenheck; Kendon J Conrad; Samuel A Ball; Marc I Rosen
Journal:  J Nerv Ment Dis       Date:  2008-07       Impact factor: 2.254

9.  Social Security Claims of Psychiatric Disability: Elements of Case Adjudication and the Role of Primary Care Physicians.

Authors:  Raphael J. Leo; Paula Del Regno
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-12

10.  A randomized controlled trial of a money management-based substance use intervention.

Authors:  Marc I Rosen; Kathleen M Carroll; Elina Stefanovics; Robert A Rosenheck
Journal:  Psychiatr Serv       Date:  2009-04       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.